What to Expect When Stitch Fix Reports After the Close
Stitch Fix is scheduled to release its fiscal fourth-quarter financial results after the markets close on Tuesday.
All Work
Chris Lange
Are Biotechs the Next Target for Cyber Criminals?
Minerva Neurosciences shares dropped sharply on Tuesday after the firm announced that it was the victim of a cyberattack. Minerva also provided an update on its clinical trials.
Major Duchenne Muscular Dystrophy Trial Is Ready to Launch
Catabasis Pharma shares jumped early on Tuesday after the firm announced that it had completed the enrollment for its late-stage Duchenne muscular dystrophy (DMD) study. Specifically, the enrollment is for the Phase 3 PolarisDMD…
Chapter 11 for Forever 21
The retail chain that embraces an eternal youthful disposition, Forever 21, may not be around for too much longer after the company voluntarily filed for Chapter 11 bankruptcy over the weekend.
Why This Finally Could Be Bed Bath & Beyond’s Time to Shine
Bed Bath & Beyond is scheduled to release its most recent quarterly results later this week. One analyst is getting out ahead of the report and believes that it is this struggling retailer’s time…
Why This Successful Bladder Cancer Study May Not Be Enough
Immunomedics shares dropped sharply on Monday after the firm presented interim data from its midstage bladder cancer study at the European Society for Medical Oncology (ESMO) Annual Congress in Barcelona, Spain.
It’s Official, WeWork Is Out
WeWork has formally filed with the SEC its intention to no longer come public. This company has been plagued by bad press as analysts have slashed its valuation over the course of this year.
Ovarian Cancer Study Suffers Big Setback
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Are Dova Pharma Investors Getting the Most Out of This Acquisition?
Dova Pharmaceuticals shares jumped on Monday after the firm announced that it would be acquired by Swedish Orphan Biovitrum, or Sobi. But are Dova investors getting enough out of this acquisition?
Bed Bath & Beyond, Constellation Brands, Costco, PepsiCo and More Earnings Coming This Week
24/7 Wall St. has put together a preview of Costco, PepsiCo and some of the other most prominent earnings reports expected this week.
Was Peloton the Final Straw for the IPO Market?
A horde of companies have come public this year expecting the best, but even with strong market tailwinds many of these firms have fallen to the wayside. Peloton was the most recent company to…
Why Analysts Like Micron Despite the Big Drop After Earnings and Guidance
Although Micron Technology investors sent shares much lower after it released fiscal fourth-quarter financial results, analysts remain cautiously positive on the stock.
Good News for Teens Suffering Atopic Dermatitis
Pfizer has announced positive top-line results from a second Phase 3 pivotal study evaluating abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis.
Why Micron Earnings Aren’t Enough
Micron Technology released better than expected fiscal fourth-quarter financial results after markets closed Thursday.
Why One Analyst Sees China As a Huge Overhang For Tech in Q3
Third quarter earnings season is coming soon for tech players, and this will take place over the next month. However, the biggest worry from investors continues to be the China black cloud which is…
Will the Markets Stay On Track in 2020?
Although 2019 is not over yet, one analyst is already making forecasts on what we have in store for 2020.
Peloton’s Underwhelming IPO
Interactive fitness platform Peloton had an inauspicious start to trading on Thursday in its initial public offering.
Is This the Beginning of a Big Beyond Meat Partnership With McDonald’s?
Beyond Meat shares jumped on Thursday after it was announced that McDonald’s will be testing a new plant, lettuce and tomato (PLT) sandwich using Beyond Meat's patties in some restaurants in Canada next week.
What to Watch When Micron Reports After the Close
Micron is set to release its most recent financial results after the markets close on Thursday, and Wall Street expectations are low.
Is This Trial Really Disappointing News for Non-Alcoholic Steatohepatitis Sufferers?
Enanta Pharma shares dropped on Thursday after the company announced topline results from its Argon-1 Phase 2a study of EDP-305 for the treatment of non-alcoholic steatohepatitis (NASH).